|
1
|
Saintigny P and Burger JA: Recent advances
in non-small cell lung cancer biology and clinical management.
Discov Med. 13:287–297. 2012.PubMed/NCBI
|
|
2
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Uzel EK, Figen M and Uzel Ö: Radiotherapy
in lung cancer: Current and future role. Sisli Etfal Hastan Tip
Bull. 53:353–360. 2019.
|
|
4
|
Mulherkar R, Grewal AS and Berman AT:
Emerging role of immunotherapy in locally advanced non-small cell
lung cancer. Clin Adv Hematol Oncol. 18:212–217. 2020.PubMed/NCBI
|
|
5
|
Friedlaender A, Kim C and Addeo A:
Rethinking the optimal duration of immune checkpoint inhibitors in
non-small cell lung cancer throughout the COVID-19 pandemic. Front
Oncol. 10:8622020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang KC and Chang HY: Molecular mechanisms
of long noncoding RNAs. Mol Cell. 43:904–914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Batista PJ and Chang HY: Long noncoding
RNAs: Cellular address codes in development and disease. Cell.
152:1298–1307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mercer TR, Dinger ME and Mattick J: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Do H and Kim W: Roles of oncogenic long
non-coding RNAs in cancer development. Genomics Inform. 16:e182018.
View Article : Google Scholar
|
|
10
|
Wang L, Ma L, Xu F, Zhai W, Dong S, Yin L,
Liu J and Yu Z: Role of long non-coding RNA in drug resistance in
non-small cell lung cancer. Thorac Cancer. 9:761–768. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang Q: Predictive relevance of ncRNAs in
non-small-cell lung cancer patients with radiotherapy: A review of
the published data. Biomark Med. 12:1149–1159. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu T, Wang Y, Chen D, Liu J and Jiao W:
Potential clinical application of lncRNAs in non-small cell lung
cancer. Onco Targets Ther. 11:8045–8052. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ghafouri-Fard S, Shoorei H, Branicki W and
Taheri M: Non-coding RNA profile in lung cancer. Exp Mol Pathol.
114:1044112020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dai SP, Jin J and Li WM: Diagnostic
efficacy of long non-coding RNA in lung cancer: A systematic review
and meta-analysis. Postgrad Med J. 94:578–587. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peng W, Wang J, Shan B, Peng Z, Dong Y,
Shi W, He D, Cheng Y, Zhao W, Zhang C, et al: Diagnostic and
prognostic potential of circulating long non-coding RNAs in non
small cell lung cancer. Cell Physiol Biochem. 49l:816–827. 2018.
View Article : Google Scholar
|
|
16
|
He R, Zhang FH and Shen N: lncRNA
FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through
suppressing E-cadherin and regulating WNT pathway in non-small cell
lung cancer (NSCLC). Biomed Pharmacother. 95:331–338. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun W, Zu Y, Fu X and Deng Y: Knockdown of
lncRNA-XIST enhances the chemosensitivity of NSCLC cells via
suppression of autophagy. Oncol Rep. 38:3347–3354. 2017.PubMed/NCBI
|
|
18
|
Ying J, Yang J and Liu Y: lncARSR promotes
non-small-cell lung cancer progression via regulating PTEN/akt. Am
J Transl Res. 12:857–866. 2020.PubMed/NCBI
|
|
19
|
Xiao B and Guo J: Long noncoding RNA
AC096655.1-002 has been officially named as gastric
cancer-associated transcript 1, GACAT1. Tumour Biol. 34:32712013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li PF, Chen SC, Xia T, Jiang XM, Shao YF,
Xiao BX and Guo JM: Non-coding RNAs and gastric cancer. World J
Gastroenterol. 20:5411–5419. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi
Y and Guo J: Long noncoding RNA associated-competing endogenous
RNAs in gastric cancer. Sci Rep. 4:60882014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi X, Wang X and Hua Y: LncRNA GACAT1
promotes gastric cancer cell growth, invasion and migration by
regulating miR-149-mediated Of ZBTB2 and SP1. J Cancer.
9:3715–3722. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Q, Xue J, Ren Q, Li X and Qiu X:
Long-chain non-coding RNA GACAT1 promotes development and
progression of breast cancer by targeting microRNA-875-3p. Oncol
Lett. 19:2547–2553. 2020.PubMed/NCBI
|
|
24
|
Zhao Y, Wang H, Wu C, Yan M, Wu H, Wang J,
Yang X and Shao Q: Construction and investigation of
lncRNA-associated ceRNA regulatory network in papillary thyroid
cancer. Oncol Rep. 39:1197–1206. 2018.PubMed/NCBI
|
|
25
|
Li F, Huang C, Li Q and Wu X: Construction
and comprehensive analysis for dysregulated long non-coding RNA
(lncRNA)-associated competing endogenous RNA (ceRNA) network in
gastric cancer. Med Sci Monit. 24:37–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Z, Qian W, Wang S, Ji D, Wang Q, Li
J, Peng W, Gu J, Hu T, Ji B, et al: Analysis of lncRNA-associated
ceRNA network reveals potential lncRNA biomarkers in human colon
adenocarcinoma. Cell Physiol Biochem. 49:1778–1791. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar :
|
|
30
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Ann Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thomson DW and Dinger ME: Endogenous
microRNA sponges: Evidence and controversy. Nat Rev Genet.
17:272–283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qi X, Zhang DH, Wu N, Xiao JH, Wang X and
Ma W: CeRNA in cancer: Possible functions and clinical
implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou Z, Lin Z, He Y, Pang X, Wang Y,
Ponnusamy M, Ao X, Shan P, Tariq MA, Li P and Wang J: The long
noncoding RNA D63785 regulates chemotherapy sensitivity in human
gastric cancer by targeting miR-422a. Mol Ther Nucleic Acids.
12:405–419. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
35
|
Schmitt AM and Chang HY: Long noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huarte M: The emerging role of lncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu M, Xiusheng H, Xiao X and Wang Y:
Overexpression of miR-422a inhibits cell proliferation and
invasion, and enhances chemosensitivity in osteosarcoma cells.
Oncol Rep. 36:3371–3378. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zheng GX, Qu AL, Yang YM, Zhang X, Zhang
SC and Wang CX: miR-422a is an independent prognostic factor and
functions as a potential tumor suppressor in colorectal cancer.
World J Gastroenterol. 22:5589–5597. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liang H, Wang R, Jin Y, Li J and Zhang S:
MiR-422a acts as a tumor suppressor in glioblastoma by targeting
PIK3CA. Am J Cancer Res. 6:1695–1707. 2016.PubMed/NCBI
|
|
40
|
Wei WT, Nian XX, Wang SY, Jiao HL, Wang
YX, Xiao ZY, Yang RW, Ding YQ, Ye YP and Liao WT: miR-422a inhibits
cell proliferation in colorectal cancer by targeting AKT1 and
MAPK1. Cancer Cell Int. 17:912017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zou Y, Chen Y, Yao S, Deng G, Liu D, Yuan
X, Liu S, Rao J, Xiong H, Yuan X, et al: MiR-422a weakened breast
cancer stem cells properties by targeting PLP2. Cancer Biol Ther.
19:436–444. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
He Z, Li Z, Zhang X, Yin K, Wang W, Xu Z,
Li B, Zhang L, Xu J, Sun G, et al: MiR-422a regulates cellular
metabolism and malignancy by targeting pyruvate dehydrogenase
kinase 2 in gastric cancer. Cell Death Dis. 9:5052018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Khachigian LM: The yin and yang of YY1 in
tumor growth and suppression. Int J Cancer. 143:460–465. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sarvagalla S, Kolapalli SP and
Vallabhapurapu S: The two sides of YY1 in cancer: A friend and a
foe. Front Oncol. 9:12302019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Meliala IT, Hosea R, Kasim V and Wu S: The
biological implications of yin yang 1 in the hallmarks of cancer.
Theranostics. 10:4183–4200. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu D, Zhang J, Wu Y, Shi G, Yuan H, Lu Z,
Zhu Q, Wu P, Lu C, Guo F, et al: YY1 suppresses proliferation and
migration of pancreatic ductal adenocarcinoma by regulating the
CDKN3/MdM2/P53/P21 signaling pathway. Int J Cancer. 142:1392–1404.
2018. View Article : Google Scholar
|
|
47
|
Grönroos E, Terentiev AA, Punga T and
Ericsson J: YY1 inhibits the activation of the p53 tumor suppressor
in response to geno-toxic stress. Proc Natil Acad Sci USA.
101:12165–12170. 2004. View Article : Google Scholar
|
|
48
|
Sui G, Affar El B and Shi Y, Brignone C,
Wall NR, Yin P, Donohoe M, Luke MP, Calvo D, Grossman SR and Shi Y:
Yin yang 1 is a negative regulator of p53. Cell. 117:859–872. 2004.
View Article : Google Scholar : PubMed/NCBI
|
